Is liver enzyme elevation common with tigecycline?
Yes, liver enzyme elevation is a common side effect of tigecycline, occurring in 2-15% of patients across clinical trials, depending on dose and duration.[1][2] Elevated transaminases (ALT/AST) typically appear within the first week of treatment and resolve after discontinuation, though monitoring is standard for at-risk patients like those with liver disease.[1]
How frequent is it in trials and real-world use?
In Phase 3 trials for complicated skin/skin structure infections and intra-abdominal infections, abnormal liver function tests affected 1-13% of tigecycline patients versus 1-7% on comparators like vancomycin or imipenem. Higher rates (up to 15%) occur with prolonged therapy (>14 days).[1][3] Post-marketing reports note rare severe cases like hepatitis, but elevations are mostly mild to moderate.[2]
Why does tigecycline raise liver enzymes?
Tigecycline, a glycylcycline antibiotic, inhibits bacterial protein synthesis but can disrupt mitochondrial function in hepatocytes, leading to transient enzyme spikes. Risk factors include obesity, diabetes, or concurrent hepatotoxic drugs.[1][4]
What do patients and doctors watch for?
Guidelines recommend baseline liver tests and weekly monitoring during therapy. Stop tigecycline if ALT/AST exceed 5x upper limit or bilirubin triples.[1][2] Patients report nausea alongside elevations, but it's reversible in most cases.
How does it compare to other antibiotics?
Tigecycline shows higher liver enzyme rates than beta-lactams (e.g., 3% vs 1% for piperacillin-tazobactam) but similar to some tetracyclines. It's less hepatotoxic than older agents like telithromycin.[3][5]
[1]: Tygacil (tigecycline) Prescribing Information, Pfizer
[2]: Drugs.com - Tigecycline Side Effects
[3]: Clinical Infectious Diseases, 2005 - Tigecycline Safety Review
[4]: Hepatology, 2010 - Mitochondrial Toxicity of Tigecycline
[5]: Journal of Antimicrobial Chemotherapy, 2009 - Comparative Hepatotoxicity